Practical utility of insulin‐like growth factor <scp>II mRNA</scp>‐binding protein 3, glucose transporter 1, and epithelial membrane antigen for distinguishing malignant mesotheliomas from benign mesothelial proliferations

Chang, Sunhee; Oh, Mee‐Hye; Ji, Sun-Young; Han, Joungho; Kim, Taejung; Eom, Minseob; Kwon, Kun Young; Ha, Seung Yeon; Choi, Yoo Duk; Lee, Chang-Hun; Lee, Yonghee; Jung, Soon-Hee

doi:10.1111/pin.12216

Cited by 20 publications

(16 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Of these, glucose transporter 1 (GLUT-1), a putative marker of malignancy, probably makes the most mechanistic sense, since it is increased in a very wide variety of malignant tumors. Unfortunately, GLUT-1 staining of mesothelial cells is confounded by staining of red cells, making interpretation difficult; and, more important, although some authors [5][6][7] claim that GLUT-1 staining is never seen in benign mesothelial reactions, our experience and that of others [8][9][10][11] ed positive for GLUT-1.…”

mentioning

confidence: 86%

New Markers for Separating Benign From Malignant Mesothelial Proliferations: Are We There Yet?

Churg

Sheffield

Galateau-Salle

2015

Archives of Pathology &Amp; Laboratory Medicine

146

153

View full text Add to dashboard Cite

The separation of benign from malignant mesothelial proliferations is crucial to patient care but is frequently morphologically difficult.Context.— To briefly review adjunctive tests claimed to be useful in this setting and to examine in detail 2 new tests: p16 fluorescence in situ hybridization (FISH) and BRCA1-associated protein 1 (BAP1) immunohistochemistry.Objective.— Literature review with emphasis on p16 FISH and BAP1 immunohistochemistry.Design.— Glucose transporter-1, p53, insulin-like growth factor 2 messenger RNA–binding protein 3 (IMP-3), desmin, and epithelial membrane antigen have all been claimed to mark either benign or malignant mesothelial processes, but in practice they at best provide statistical differences in large series of cases, without being useful in an individual case. Homozygous deletion of p16 by FISH or loss of BAP1 has only been reported in malignant mesotheliomas and not in benign mesothelial proliferations. BAP1 appears to be lost more frequently in epithelial than mixed or sarcomatous mesotheliomas. Homozygous deletion of p16 by FISH is seen in pleural epithelial, mixed, and sarcomatous mesotheliomas, but it is much less frequent in peritoneal mesothelioma. The major drawback to both these tests is limited sensitivity; moreover, failure to find p16 deletion or BAP1 loss does not make a mesothelial process benign.Results.— In the context of a mesothelial proliferation, the finding of homozygous deletion of p16 by FISH or loss of BAP1 by immunohistochemistry is, thus far, 100% specific for malignant mesothelioma. The limited sensitivity of each test may be improved to some extent by running both tests.Conclusions.—

show abstract

mentioning

confidence: 86%

New Markers for Separating Benign From Malignant Mesothelial Proliferations: Are We There Yet?

Churg

Sheffield

Galateau-Salle

2015

Archives of Pathology &Amp; Laboratory Medicine

146

153

View full text Add to dashboard Cite

show abstract

“…Increased GLUT-1 expression is thought to be associated with abnormally high constitutive glucose uptake and metabolism, processes that are mediated by known GLUT isoforms 13,[15][16][17]19 .…”

Section: Discussionmentioning

confidence: 99%

“…Immunohistochemistry was performed as reported previously 16,17 . Formalin-fixed, paraffinembedded tissues were cut into 4-µm-thick sections, deparaffinized in xylene, rehydrated by passage through decreasing concentrations of alcohol, and nally placed in distilled water.…”

Section: Immunohistochemistry and Immunohistochemical Analysismentioning

confidence: 99%

GLUT-1 Expression as an Independent Predictor of Outcome in Patients with R1 Pancreatic Ductal Adenocarcinoma

Ito

Tajiri

Muraki

et al. 2016

Showa Univ J Med Sci

View full text Add to dashboard Cite

: At present, there is no way to definitely know whether microscopic residual tumors R1 disease are present following pancreatectomy performed for the treatment of pancreatic ductal adenocarcinoma PDAC . Therefore, we investigated whether the expression of the glucose transporter-1 protein GLUT-1 could be used as a prognostic indicator for R1 PDAC. We retrospectively examined the association between overall survival OS , clinicopathological factors, and GLUT-1 expression in 68 patients with resectable PDAC total PDAC group and in a subset of 28 patients with R1 disease R1 PDAC group . The presence of R1 disease signi cantly in uenced the OS rates of patients in the total PDAC group, but GLUT-1 expression did not. However, the median OS time was signi cantly shorter for GLUT-1-positive patients in the R1 PDAC group. GLUT-1 expression was found to be an independent predictor of decreased survival time P 0.020 . We propose that GLUT-1 expression testing will facilitate development of treatment plans for R1 PDAC patients.

show abstract

“…GLUT-1 has been investigated by many groups for MPM differential diagnosis, and it has continuously shown high specificity for MPM (90-100%), while its sensitivity values ranged from 21% to 85% (5)(6)(7)(8).…”

Section: Diagnostic Markers By Ihc or Fishmentioning

confidence: 99%

“…The presence of an IMP-3 protein is indicative of MPM with a sensitivity of 37% to 94%, regardless of subtype and location. However, some benign reactions, particularly for atypical hyperplasia, stain for this marker as well (5,6,11,13).…”

Section: Diagnostic Markers By Ihc or Fishmentioning

confidence: 99%

Molecular markers and new diagnostic methods to differentiate malignant from benign mesothelial pleural proliferations: a literature review

Bruno¹,

Alì²,

Fontanini³

2018

J. Thorac. Dis.

View full text Add to dashboard Cite

Malignant pleural mesothelioma (MPM) is an aggressive tumor associated with asbestos exposure. Histopathological analysis of pleural tissues is the gold standard for diagnosis; however, it can be difficult to differentiate malignant from benign pleural lesions. The purpose of this review is to describe the most important biomarkers and new diagnostic tools suggested for this differential diagnosis. There are many studies concerning the separation between MPM and benign pleural proliferations from both pleural tissues or effusions; most of them are based on the evaluation of one or few biomarkers by immunohistochemistry (IHC) or enzyme-linked immunosorbent assays (ELISAs), whereas others focused on the identification of MPM signatures given by microRNA (miRNA) or gene expression profiles as well as on the combination of molecular data and classification algorithms. None of the reported biomarkers showed adequate diagnostic accuracy, except for p16 [evaluated by fluorescent in situ hybridization (FISH)] and BAP1 (evaluated by IHC), both biomarkers are recommended by the International Mesothelioma Interest Group guidelines for histological and cytological diagnosis. BAP1 and p16 showed a specificity of 100% in discerning malignant from benign lesions because they are exclusively unexpressed or deleted in MPM. However, their sensitivity, even when used together, is not completely sufficient, and absence of their alterations cannot confirm the benign nature of the lesion. Recently, the availability of new techniques and increasing knowledge regarding MPM genetics led to the definition of some molecular panels, including genes or miRNAs specifically deregulated in MPM, that are extremely valuable for differential diagnosis. Moreover, the development of classification algorithms is facilitating the application of molecular data for clinical practice. Data regarding new diagnostic tools and MPM signatures are absolutely promising; however, before their application in clinical practice, a prospective validation is necessary, as these approaches could surely improve the differential diagnosis between malignant and benign pleural lesions.

show abstract

Practical utility of insulin‐like growth factor II mRNA‐binding protein 3, glucose transporter 1, and epithelial membrane antigen for distinguishing malignant mesotheliomas from benign mesothelial proliferations

Cited by 20 publications

References 29 publications

New Markers for Separating Benign From Malignant Mesothelial Proliferations: Are We There Yet?

New Markers for Separating Benign From Malignant Mesothelial Proliferations: Are We There Yet?

GLUT-1 Expression as an Independent Predictor of Outcome in Patients with R1 Pancreatic Ductal Adenocarcinoma

Molecular markers and new diagnostic methods to differentiate malignant from benign mesothelial pleural proliferations: a literature review

Contact Info

Product

Resources

About